This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and presentations at ASCO.
Lilly Begins Coronavirus Study to Evaluate Antibody Therapy
by Zacks Equity Research
Lilly (LLY) initiates dosing in a phase I study to evaluate an antibody candidate for treating COVID-19.
Gilead Down on Mixed Results From Coronavirus Drug Remdesivir
by Zacks Equity Research
Gilead's (GILD) shares decline on mixed results from a late-stage study on coronavirus drug.
Regeneron Expands Deal With Intellia for Hemophilia Treatments
by Zacks Equity Research
Regeneron (REGN) expands partnership with Intellia Therapeutics to co-develop potential hemophilia A and B treatments.
Coronavirus Treatment Search Still on, Lilly, Gilead Give Updates
by Kinjel Shah
Lilly (LLY) begins phase I study on a potential antibody therapy to treat COVID-19. Gilead (GILD) announces mixed results from the second phase III study on remdesivir in patients with moderate COVID-19.
Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Box, Ulta Beauty, Merck, Gilead and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
Markets Neutral to Kick Off New Week & Month
by Mark Vickery
Increased levels of stress both at home and abroad aren't exactly being shrugged off by the market, but they're not being particularly negatively affected either.
Market Awaits Major Economic Data This Week
by Zacks Equity Research
Market Awaits Major Economic Data This Week
Drugmakers Focus on Coronavirus Vaccine by 2020: 4 Winners
by Ritujay Ghosh
Clinical trials of non-COVID-19 drugs have taken a backseat as most drugmakers and biotechnology companies are speeding up development of a vaccine for the novel coronavirus.
Merck (MRK) Shares Looking Ripe For A Buy
by Daniel Laboe
Merck (MRK) is a pharmaceutical powerhouse that has been under-appreciated amid this health crisis
Why Is Gilead (GILD) Down 7.3% Since Last Earnings Report?
by Zacks Equity Research
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Roche Starts Study on Actemra with Gilead's Drug for Coronavirus
by Zacks Equity Research
Roche (RHHBY) commences a phase III study on Actemra with Gilead's remdesivir in hospitalized patients with severe COVID-19 pneumonia.
Zacks.com featured highlights include: TakeTwo Interactive Software, Gilead Sciences and Regeneron Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights include: TakeTwo Interactive Software, Gilead Sciences and Regeneron Pharmaceuticals
Gilead Inks 10-Year Deal With Arcus for Immuno-oncology Drugs
by Zacks Equity Research
Gilead (GILD) looks to expand presence in the immune-oncology space with a 10-year partnership with Arcus.
The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology
3 Top-Ranked Stocks With Upgraded Broker Ratings to Buy Now
by Swayta Shah
It is advisable to follow broker ratings to find attractive stocks, given the uncertain operating backdrop.
Intercept Down on Postponement of AdCom Meet for NASH Drug
by Zacks.com
The FDA defers advisory committee meeting date pertaining to Intercept's (ICPT) NDA for obeticholic acid to treat liver fibrosis due to nonalcoholic steatohepatitis.
Regeneron (REGN) to Buy Back Part of Its Stake Held by Sanofi
by Zacks Equity Research
Regeneron (REGN) commences underwritten public secondary offering of its common stock held by Sanofi and repurchases shares for $5 billion.
Pre-Markets Race Higher on Vaccine Hopes
by Mark Vickery
Chief among positives for the market is a new vaccine candidate for COVID-19 from Novavax (NVAX), which is launching its human trials in Australia.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge
Coronavirus Vaccine Efforts Continue, Novavax Begins Human Trial
by Kinjel Shah
As several pharma/biotech companies speed up efforts to make a vaccine for COVID-19, Novavax (NVAX) begins human testing of its candidate, NVX-CoV2373.
Coronavirus Vaccine Development Gathers Steam: 4 Winners
by Ritujay Ghosh
Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (GILD) Outperforming Other Medical Stocks This Year?
Gilead (GILD) Gains 13% YTD on Coronavirus Drug Development
by Zacks Equity Research
Gilead's experimental coronavirus drug, remdesivir, shows promise. The stock has been in news since the onset of the year on updates from the same.
Can Teva (TEVA) Return to Growth in This Year or Next?
by Zacks Equity Research
Though Teva (TEVA) faces several challenges, with encouraging progress on restructuring activities and stabilization in the generics business, it may return to growth in 2020 or 2021.